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Abstract: Tuberculosis (TB) remains a public health problem in Tunisia. Its incidence is higher 
in immunocompromised hosts than in the general population. In children and during hemo-
dialysis, TB is characterized by the frequency of extrapulmonary localizations and diagnostic 
difficulties. The aim of this retrospective study is to evaluate the incidence of TB in Tunisian 
children undergoing hemodialysis and to determine its clinical features as well as the results 
of chemotherapy.
Method: This retrospective study includes seven TB children among 112 children on hemodi-
alysis at the pediatric nephrology department in Charles Nicolle Hospital from 2002 to 2008. 
The diagnosis of TB was established by a combination of clinical, radiological, biochemical, 
microbiological, and histological examinations. Treatment with anti-TB drugs, the results of 
therapy, and the outcome of patients were noted.
Results: There were four girls and three boys aged 10 to 16 years (mean, 13 years). They had 
been on hemodialysis for 2 to 5 years (mean, 3 years). Noted clinical features were weight loss 
and fever in five cases, chest pain in one case, cervical lymph node in one case, and spinal pain 
in one case. The organ systems involved were pleural in two cases, pulmonary in one case, 
peritoneal in one case, cervical lymphatic in one case, and spinal in one case. One patient was 
treated empirically with a good response. Diagnosis was made by isolation of mycobacterium 
TB in three cases, by specific histological signs observed in a lymph node biopsy in one case, 
in peritoneal biopsy in one case, and in discovertebral biopsy in one case. In the remain-
ing patient, the clinical and radiological presentations were compatible with pulmonary TB. All 
patients received four anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol. One 
patient died with miliary TB. The other patients had favorable outcomes.
Conclusions: TB in hemodialysis children has a nonspecific clinical presentation. Extrapul-
monary locations are most common. Diagnosis is often difficult, but successful outcomes are 
possible when made at an early stage.
Keywords: child, hemodialysis, tuberculosis
Introduction
The incidence of tuberculosis (TB) decreased in recent years in Tunisia due to effec-
tive vaccination. The annual incidence is estimated at 3.5 per 100,000 children.1 
Immunocompromised patients, such as those with end-stage renal failure requiring 
hemodialysis, have an increased risk of developing TB infection. This risk has been 
estimated as nearly 10- to 25-fold higher among hemodialysis patients than among 
the general population.2 We report the incidence of TB in normal children as well as in 
hemodialysis children. We discuss the clinical characteristics, diagnostic procedures, 
and clinical outcomes for TB children on hemodialysis.International Journal of Nephrology and Renovascular Disease 2010:3 48
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Patients and methods
We retrospectively analyzed all hemodialysis patients 
aged less than 18 years in whom the diagnosis of TB was 
presumptive or confirmed from January 2002 to December 
2008. One hundred twelve patients were enrolled. Seven 
patients were diagnosed with TB. Of these, three cases 
were considered presumptive, three patients were noted to 
have positive mycobacterium TB culture, and the other was 
empirically treated for TB with a good response. The fol-
lowing data were collected for each patient: epidemiologi-
cal characteristics, risk factors, duration of hemodialysis, 
clinical symptoms, diagnostic methods, treatment, and TB 
evolution.
Results
Among 112 children treated with hemodialysis during the 
study period, we noted seven cases (25%) of TB disease: 
four females and three males with an average age of 13 years 
(range, 10–16 years). Their duration on hemodialysis ranged 
from 2 to 5 years (mean, 3 years). The presenting clinical 
features were weight loss and fever in five cases, chest pain 
in one case, spinal pain in one case, and cervical lymphade-
nopathy in one case. Tuberculin skin test was negative in all 
patients. Chest X-ray showed an abundant pleural effusion in 
two cases and a miliary TB in one case. In these three patients, 
sputum samples were smear-negative. The fluid from patients 
with pleurisy showed exudates rich in lymphocyte (95%). 
Acid-fast smears using Zeihl–Neelsen acid fast stain and 
culture in Lowenstein–Jensen medium were performed but 
proved to be negative. Caseous granulomas were found in 
pleural biopsy in our patients with TB pleurisy. The culture 
of tissue biopsy specimens revealed mycobacterium TB in 
both patients. In patients with peritoneal TB, the diagnosis 
was established by data from the peritoneal biopsy done by 
laparoscopy (caseous granulomas).
In the case of miliary TB, sputum culture was positive. 
In another patient, the clinical and radiological presentations 
were compatible with pulmonary TB. Noted improvement 
after anti-TB therapy confirmed this diagnosis. The clinical 
characteristics of our patients are illustrated in Table 1.
Four drugs, isoniazid (INH), rifampicin (RIF), pyrazin-
amide (PZA), and ethambutol (EMB) were administered 
orally to six patients initially for three months followed by 
only INH and RIF for a further six months to complete a nine-
month therapy. Drugs were administered on dialysis days 
following the session of dialysis (three days per week). The 
outcome was favorable. In one patient with miliary TB, INH 
and RIF was used intravenously. He died at the beginning 
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of treatment. TB was considered as the direct cause of death 
for this patient.
Discussion
Uremic adults are more susceptible to TB infection due 
to pathological changes in the airways and impairment in 
cellular immunity.3 Dialysis increases these immunological 
impairments through depletion of useful proteins, trace met-
als, and vitamins; it also induces an immune response through 
biocompatibility of dialysis membrane and dialysis fluid or 
entry of microorganisms.4 Few data are available for uremic 
children. To our knowledge, nothing has been published in 
the English literature on TB in hemodialysis children. How-
ever, the most recent publication about the child on dialysis 
reported four cases of TB in children undergoing continuous 
ambulatory peritoneal dialysis in Turkey.5 According to this 
study, the incidence of TB in children on dialysis is much 
lower than in adults on dialysis (23.6% versus 5.7%). This 
has been attributed to the vaccination program which begins 
at the age of two months and repeated at the age of seven 
and 12 years. In Tunisia, the vaccination schedule is similar 
to Turkey apart from the first dose being given immediately 
at birth then improving immunization at an early age and 
before the installation of chronic renal disease.
The emergence of TB infection in uremic adults is 
observed during the early years of hemodialysis. During 
this phase, the cell-mediated immunity is compromised and 
promotes infection, especially TB.6 Mesiha and colleagues5 
studied children undergoing peritoneal dialysis, and noted 
that the diagnosis of TB was made during the first year 
of dialysis in three patients and before dialysis in another 
patient. In our study, TB infection took place 24 months after 
beginning hemodialysis.
The mode of contamination is probably a reactivation of 
a pre-existing focus but in our study, the TB may be due to 
an airborne spread in the hospital community with respect 
to the interval between the beginning of dialysis and diag-
nosis of TB.
Clinical presentation of TB may be insidious and 
nonspecific, mimicking uremic symptoms. There are clini-
cal situations that alert us to the presence of TB such as 
unexplained fever, anorexia, deterioration of nutritional 
heath, and spinal pain which is often associated to renal 
osteodystrophy.
The diagnosis of TB is difficult to establish in the case of 
renal failure by simply using traditional tests. The tuberculin 
skin test is often negative. Bacteriological proof is rarely 
obtained by traditional tests such as Zeihl–Neelsen staining, 
culture, or polymerase chain reaction.7 Thus, new, rapid, and 
it is imperative to utilize accurate diagnostic methods such as 
blood test measuring the interferon-γ released by stimulated 
T cells.8 In our study, and because of the unavailability of 
these modern methods, invasive diagnostic procedures were 
performed to prove the TB infection: pleural biopsy, peri-
toneal biopsy, and percutaneaous disc biopsy. Histopatho-
logical examination and culture of tissue obtained by biopsy 
identified the mycobacterium TB in two cases.
TB has been described in uremic patients along with an 
infection with predominantly extra pulmonary involvement.9 
During dialysis, pulmonary TB with cavities was minor 
whereas extrapulmonary TB and miliary TB were major.10 
Our data confirm these findings since we found only two 
patients with pulmonary TB among seven cases.
Apart from the diagnostic difficulties, TB in patients 
undergoing hemodialysis have a real therapeutic problem. 
The bioavailability of most drugs are altered by renal failure 
and hemodialysis. The half-life of INH is prolonged in end-
stage renal disease.11 Consequently, some researchers12 use 
INH in half doses (5 mg/kg) per day. However, others prefer 
to use the full dose.
In our study, we prescribe a full dose with good toler-
ance even in slow acetylates. We recommend giving the 
dose of INH on dialysis days after the dialysis session. The 
neurological side effects of INH are preventable by adding 
pyridoxine in doses of 50 mg per day (half of the recom-
mended adult dose).
The usual dose of RIF is recommended because its 
metabolism does not depend on renal function.13 EMB is 
usually given in a dose of 20 mg/kg three times a week 
after each hemodialysis session. In the same way, we can 
prescribe the PZA at a dose of 20 to 25 mg/kg.13 In children 
on dialysis, the duration of treatment in accordance with 
new recommendations is 12 months (with INH and RIF and 
with EMB and PZA added for the first two months).5 We 
strongly recommend this protocol to avoid the resistance 
and resurgence of TB after kidney transplantation. The 
efficiency of this protocol is only possible if the treatment 
is well monitored and tolerated.14 In our study, the outcome 
was fatal for a patient with miliary TB despite intravenous 
INH and RIF.
Conclusion
Dialysis patients and especially children are at high risk of 
TB. Physicians caring for dialysis children must remain vigi-
lant for signs of TB in this vulnerable population. Two basic 
points emerge throughout our study and literature review:International Journal of Nephrology and Renovascular Disease 2010:3
International Journal of Nephrology and Renovascular Disease
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1.  Diagnostic difficulties of the disease are due to the insidious 
and nonspecific clinical presentation and difficulties in iden-
tifying the mycobacterium TB by conventional methods.
2.  The outcome is often favorable when treatment starts at 
an early stage and the duration is long enough.
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